CHAPEL HILL, N.C.--(BUSINESS WIRE)--Feb. 14, 2008--POZEN Inc.
(NASDAQ:POZN) announced today that John R. Plachetka Pharm.D., the
company's chairman, president and chief executive officer, will
present at Susquehanna Financial Group's Second Annual SIGnificant
Options in Healthcare Conference on Tuesday, March 4, 2008 at 12:30
p.m. (ET) at the W Hotel in New York.
POZEN is a pharmaceutical company committed to developing
therapeutic advancements for diseases with unmet medical needs where
it can improve efficacy, safety, and/or patient convenience. POZEN's
efforts are focused primarily on the development of pharmaceutical
products for the treatment of acute and chronic pain and other
pain-related conditions. POZEN has development and commercialization
alliances with GlaxoSmithKline for the proposed product candidate
Treximet(TM) which is currently under review by the United States Food
and Drug Administration for the acute treatment of migraine, and with
AstraZeneca for the proposed product candidate PN 400 for conditions
such as osteoarthritis and rheumatoid arthritis in patients who are at
risk for developing NSAID-associated gastric ulcers. The company's
common stock is traded on The Nasdaq Stock Market under the symbol
"POZN". For detailed company information, including copies of this and
other press releases, see POZEN's website: www.pozen.com.
CONTACT: POZEN Inc.
Bill Hodges, Chief Financial Officer, 919-913-1030;
Fran Barsky, Director, Investor Relations, 919-913-1044
SOURCE: POZEN Inc.